Skip to main content

Marvel Biosciences Corp(MRVL-X)
TSX Venture

Today's Change
Delayed Last Update
Day Low0.140
Day High0.140
Open:0.140
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change

TOP STORIES: Marvel Biosciences Corp

Select a category then submit the form to load news
Newsfile
Marvel Biosciences Sponsors Scientific Meeting on Purines
INK Research
Off-market insider buying at Marvel Biosciences (MRVL)
Company Chart of MRVL
Newsfile
Marvel Biosciences Announces Grant of Deferred Share Units
Newsfile
Marvel Biosciences Secures Funding to Develop Child-Friendly Liquid Formulation for Neurodevelopmental Disorders
Newsfile
Marvel Biosciences Receives Japanese Patent Covering Composition of Matter for Its Lead Therapeutic Candidate MB-204
Newsfile
Bourse de Toronto, Marvel Biosciences Corp., Perspective de la haute direction
Newsfile
Updated Upcoming Meeting Dates - December 15, 2025
Newsfile
Upcoming Meeting Dates - December 15, 2025
Newsfile
Marvel Biosciences Announces Grant of Deferred Share Units
Newsfile
Marvel Biosciences Announces Acceleration of Warrant Expiry Date
Newsfile
Marvel Biosciences Granted Chinese Patent for Lead Therapeutic Candidate MB-204
Newsfile
Marvel Biosciences Announces Grant of Deferred Share Units
AI-generated - The Globe and Mail
Marvel Biosciences: Top 10 Undervalued Biotechnology Industry Stocks (MRVL)
AI-generated - The Globe and Mail
Marvel Biosciences: Top 10 Undervalued Biotechnology Industry Stocks (MRVL)
AI-generated - The Globe and Mail
Marvel Biosciences: Top 10 Undervalued Biotechnology Industry Stocks (MRVL)
Newsfile
Marvel Biosciences Announces Closing of Private Placement
Newsfile
Marvel Biosciences Announces Closing of Second Tranche of Private Placement
Newsfile
Marvel Announces the Second of Two Final Data Sets from Rett Syndrome Study: MB-204 Significantly Outperforms Trofinetide Following Cessation of Drug Treatment
AI-generated - The Globe and Mail
Marvel Biosciences: Top 10 Undervalued Biotechnology Industry Stocks (MRVL)
Newsfile
Marvel Biosciences to Give Oral Presentation at The Annual IRSF Rett Syndrome Scientific Meeting
Newsfile
Marvel Biosciences Selected to Present Alzheimer's Research at the 2025 Alzheimer's Association International Conference
Newsfile
Marvel Biosciences Announces Private Placement
AI-generated - The Globe and Mail
Marvel Biosciences: Top 10 Undervalued Biotechnology Industry Stocks (MRVL)
Newsfile
Marvel to File for Orphan Drug Designation with The U.S. FDA for MB-204 as a Treatment for Rett Syndrome
Newsfile
Marvel Announces First of Two Final Data Sets from Rett Syndrome Study: MB-204 Significantly Outperforms Trofinetide
Newsfile
Marvel Presenting at the 2025 Bloom Burton & Co. Conference
AI-generated - The Globe and Mail
Marvel Biosciences: Top 10 Undervalued Biotechnology Industry Stocks (MRVL)
AI-generated - The Globe and Mail
Marvel Biosciences: Top 10 Undervalued Healthcare Sector Stocks on TSX-V (MRVL)
AI-generated - The Globe and Mail
Marvel Biosciences: Top 10 Undervalued Biotechnology Industry Stocks (MRVL)
AI-generated - The Globe and Mail
Marvel Biosciences: Top 10 Undervalued Healthcare Sector Stocks on TSX-V (MRVL)
Newsfile
Marvel Biosciences Announces Notice of Allowance of Composition of Matter Patent for Its Lead Molecule MB-204 in China
Newsfile
Marvel Biosciences Announces Private Placement for up to $2.5 Million

Profile

Marvel Biosciences Corp is a biotechnology company incorporated in Canada. The Company is currently a pre-clinical stage pharmaceutical development company that utilizes a drug redevelopment approach to identify and evaluate potential therapeutic compounds. Its activities mainly involve scientific research and pre-clinical studies aimed at determining viable active compounds for further drug development.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.